Bortezomib vs Ixazomib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Proteasome · full Multiple Myeloma pipeline
Bortezomib
Marketed by Takeda Pharmaceutical Company and partners
NCT00048230 · Phase 3 · completed
APEX randomized 620 patients with relapsed multiple myeloma to bortezomib or high-dose dexamethasone in an open-label design. Its primary endpoint, time to progression, is a clinical outcome and was met. An open-label trial is never graded strong under the rubric, so the grade is moderate.
Next expected readout: November 2026 · NCT06505369 (registry estimate)
Reported efficacy
Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73 (met)
Result source: NCT00722566
Ixazomib
Marketed by Takeda Pharmaceutical Company and partners
NCT01564537 · Phase 3 · completed
Participants were randomly assigned and quadruple-blinded to ixazomib plus lenalidomide and dexamethasone or matching placebo plus lenalidomide and dexamethasone, with 360 and 362 participants, respectively. The hard clinical primary endpoint of independently assessed progression-free survival was met: median progression-free survival was 20.6 versus 14.7 months, with a statistically significant difference between groups (p=0.012).
Next expected readout: March 2027 · NCT04068597 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47) (met)
Result source: NCT02312258
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bortezomib | Ixazomib |
|---|---|---|
| PFS, median | 11.2 vs 7.1vs BTZ+LD-DEXNCT0173492814 other results
| 20.6 vs 14.7+5.9 vs placeboNCT0156453713 other results
|
| OS, median | 83.0 vs 53.6vs Velcade, Melphalan and PrednisoneNCT0219547910 other results
| 53.6 vs 51.6+2 vs placeboNCT015645376 other results
|
| ORR | 90.9% vs 73.9%vs Velcade, Melphalan and PrednisoneNCT0219547912 other results
| 78.3% vs 71.5%+6.8 vs placeboNCT0156453710 other results
|
| VGPR or better | 71.1% vs 49.7%vs Velcade, Melphalan and PrednisoneNCT021954798 other results
| 48.1% vs 39%+9.1 vs placeboNCT015645372 other results
|
| MRD negativity | 53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)NCT036520645 other results
| 59% vs 50%+9 vs placeboNCT018505243 other results
|
PFS, median
- Bortezomib
- 11.2 vs 7.1vs BTZ+LD-DEXNCT01734928
14 other results
- 13.9 vs 9.5 NCT03110562
- 46.7 NCT02541383
- 14.7 NCT00507416
- 15.4 NCT00507416
- 17.3 NCT00507416
- 36.4 vs 19.3 NCT02195479
- 6.6 vs 8.8 NCT03110562
- 22.5 vs 22.1 NCT01539083
- 3.9 vs 8.8 NCT03110562
- 9.9 vs 12.6 NCT00813150
- 52.8 NCT02541383
- 3.9 NCT03110562
- 8.1 vs 7.6 NCT00401843
- 15.3 NCT02290431
- Ixazomib
- 20.6 vs 14.7+5.9 vs placeboNCT01564537
13 other results
- 35.3 vs 21.8 NCT01850524
- 26.5 vs 21.3 NCT02181413
- 17.4 vs 9.4 NCT02312258
- 18.7 vs 9.3 NCT01564537
- 10.1 vs 9.6 NCT02312258
- 21.3 NCT03748953
- 7.1 vs 4.8 NCT03170882
- 29.0 vs 29.0 NCT03416374
- 5.2 NCT02477215
- 22.1 NCT02917941
- 23.5 NCT02046070
- 23 NCT02046070
- 14.2 NCT02046070
OS, median
- Bortezomib
- 83.0 vs 53.6vs Velcade, Melphalan and PrednisoneNCT02195479
10 other results
- 49.6 vs 38.5 NCT02136134
- 35.6 vs 31.6 NCT01734928
- 36.7 vs 32.8 NCT03110562
- 41.5 NCT00813150
- 30.8 NCT00103506
- 33 NCT00103506
- 49.8 NCT00507416
- 51.5 NCT00507416
- 53.1 NCT00507416
- 30.8 vs 36.8 NCT00401843
- Ixazomib
- 53.6 vs 51.6+2 vs placeboNCT01564537
6 other results
- 64.8 vs 69.5 NCT02312258
- 42.2 vs 29.4 NCT01564537
- 46.9 vs 30.9 NCT01564537
- 37.3 vs 48.3 NCT02312258
- 18.8 NCT03170882
- 23.2 NCT02477215
ORR
- Bortezomib
- 90.9% vs 73.9%vs Velcade, Melphalan and PrednisoneNCT02195479
12 other results
- 82.9% vs 63.2% NCT02136134
- 76.4% vs 62.3% NCT03110562
- 70.2% vs 74.4% NCT00813150
- 19% NCT03110562
- 73% NCT00507416
- 80% NCT00507416
- 70% NCT00507416
- 88.1% NCT03412565
- 90.8% NCT03412565
- 55% vs 46.7% NCT00401843
- 80.6% NCT02290431
- 97% NCT03412565
- Ixazomib
- 78.3% vs 71.5%+6.8 vs placeboNCT01564537
10 other results
- 82% vs 80% NCT01850524
- 49% NCT02046070
- 63% NCT01864018
- 38% vs 41% NCT03170882
- 73.3% vs 71.8% NCT03416374
- 28% NCT02477215
- 84.4% NCT02917941
- 35% NCT02765854
- 35% NCT02765854
- 73% NCT02765854
VGPR or better
- Bortezomib
- 71.1% vs 49.7%vs Velcade, Melphalan and PrednisoneNCT02195479
8 other results
- 59.2% vs 29.1% NCT02136134
- 44.6% vs 32.4% NCT03110562
- 37% NCT00507416
- 51% NCT00507416
- 41% NCT00507416
- 71.6% NCT03412565
- 77.6% NCT03412565
- 80% NCT03412565
- Ixazomib
- 48.1% vs 39%+9.1 vs placeboNCT01564537
2 other results
- 50% NCT02917941
- 42.2% vs 43.6% NCT03416374
MRD negativity
- Bortezomib
- 53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)NCT03652064
5 other results
- 60.9% vs 39.4% NCT03652064
- 28.3% vs 7% NCT02195479
- 13.5% vs 2.8% NCT02136134
- 25.4% NCT03412565
- 21.5% NCT03412565
- Ixazomib
- 59% vs 50%+9 vs placeboNCT01850524
3 other results
- 6% vs 3% NCT02312258
- 18% NCT02389517
- 31% NCT02389517
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
19 other shared endpoints and safety
Coverage. Bortezomib: 23 of 23 rows · Ixazomib: 23 of 23 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bortezomib Rows use multiple source trials | Ixazomib Rows use multiple source trials |
|---|---|---|
| Complete responder rate · % of participants | 53.1% (n=98) vs 51% (n=96) Thalidomide + Prednisolone @ 52wka,b NCT01539083 · Phase 3 · registry result, not featured evidence · combination 1 other source trial10.7% (n=131) vs 7.3% (n=137) placebo NCT00401843 · Phase 2 · registry result, not featured evidence · combination | 26% (n=351) vs 14% (n=354) placeboa,b NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 |
| Duration of Response time to event · months | NA vs 21.3 Velcade, Melphalan and Prednisone monthsa,b NCT02195479 · Phase 3 · registry result, not featured evidence · combination 3 other source trials13.7 vs 10.94 BTZ+LD-DEX months NCT01734928 · Phase 3 · registry result, not featured evidence · combination 17.28 vs 12.88 Bortezomib + Dexamethasone months NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 NA vs NA Lenalidomide+Bortezomib+Dexamethasone months NCT02874742 · Phase 2 · registry result, not featured evidence · combination | 26 vs 21.7 placebo monthsa,b NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 3 other source trials50.6 vs 37.5 placebo months NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 28.03 vs 15.31 Bortezomib + Lenalidomide + Dexamethasone months NCT03416374 · Phase 4 · registry result, not featured evidence · combination 14.8 vs 14.3 Pomalidomide months4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination |
| Duration of Response time to event · months No placebo or comparator arm | 18.3 monthsc,d,a,b NCT00507416 · Phase 3 · registry result, not featured evidence · combination show 2 more doses19.8 months NCT00507416 · Phase 3 · registry result, not featured evidence · combination 22.4 months NCT00507416 · Phase 3 · registry result, not featured evidence · combination | 22.92 months*c,d,a,b NCT02389517 · Phase 2 · registry result, not featured evidence · combination · converted to months from 1.91 years as posted show 1 more dose23.76 months* NCT02389517 · Phase 2 · registry result, not featured evidence · converted to months from 1.98 years as posted |
| EORTC QLQ-C30 GHS absolute change · score | 9.8 vs 8.9 Velcade, Melphalan and Prednisone score @ 208wka,e,b NCT02195479 · Phase 3 · registry result, not featured evidence · combination | -4.1 vs -1.7 placebo scorea,e,b NCT02181413 · Phase 3 |
| MRD Negative responder rate · % of participants No placebo or comparator arm | 25.4% (n=67)c,a,b NCT03412565 · Phase 2 · registry result, not featured evidence · combination show 1 more dose21.5% (n=65) NCT03412565 · Phase 2 · registry result, not featured evidence · combination | 18% (n=11) @ 52wkc,a,b NCT02389517 · Phase 2 · registry result, not featured evidence · combination show 1 more dose31% (n=13) @ 52wk NCT02389517 · Phase 2 · registry result, not featured evidence |
| ORR event count · % of participants No placebo or comparator arm | 42.5% (n=73)*c,d,a,e,b NCT00722566 · Phase 3 · converted to % from 31 Participants as posted show 1 more dose42.1% (n=145)* NCT00722566 · Phase 3 · converted to % from 61 Participants as posted | 100% (n=12) @ 104wk*d,a,e,b NCT02412228 · Phase 2 · registry result, not featured evidence · combination · converted to % from 12 Participants as posted |
| ORR responder rate · % of participants No placebo or comparator arm | 19% (n=63)d,a,b NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 7 other source trials73% (n=147) NCT00507416 · Phase 3 · registry result, not featured evidence · combination 70% (n=145) NCT00507416 · Phase 3 · registry result, not featured evidence · combination 80% (n=133) NCT00507416 · Phase 3 · registry result, not featured evidence · combination 88.1% (n=67) NCT03412565 · Phase 2 · registry result, not featured evidence · combination 97% (n=67) NCT03412565 · Phase 2 · registry result, not featured evidence · combination 90.8% (n=65) NCT03412565 · Phase 2 · registry result, not featured evidence · combination 80.6% (n=31) @ 24wk NCT02290431 · Phase 2 · registry result, not featured evidence · combination | 73% (n=27) @ 52wkc,d,a,b NCT02765854 · Phase 2 · registry result, not featured evidence show 2 more doses35% (n=22) @ 52wk NCT02765854 · Phase 2 · registry result, not featured evidence 35% (n=21) @ 52wk NCT02765854 · Phase 2 · registry result, not featured evidence · combination |
| Overall Survival responder rate · % of participants | 83.7% (n=257) vs 85.4% (n=254) RVD @ 165wkd,f,e,g NCT01109004 · Phase 3 · registry result, not featured evidence | 94.7% (n=21) vs 86.4% (n=22) placebo @ 91wkd,f,e,g NCT02440464 · Phase 2 · registry result, not featured evidence |
| Overall Survival time to event · months No placebo or comparator arm | 33 monthsc,a,b NCT00103506 · Phase 3 · registry result, not featured evidence · combination show 1 more dose30.8 months NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy | NA monthsa,b NCT03748953 · Phase 3 · registry result, not featured evidence 9 other source trialsNA months NCT01415882 · Phase 2 · registry result, not featured evidence · combination NA months NCT01415882 · Phase 2 · registry result, not featured evidence · combination NA months NCT01415882 · Phase 2 · registry result, not featured evidence · combination NA months NCT01415882 · Phase 2 · registry result, not featured evidence · combination NA months NCT01415882 · Phase 2 · registry result, not featured evidence · combination NA months NCT02389517 · Phase 2 · registry result, not featured evidence · combination NA months NCT02389517 · Phase 2 · registry result, not featured evidence NA months4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination 23.2 months90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| PFS responder rate · % of participants | 53.9% (n=257) vs 57.8% (n=254) RVD @ 165wkd,f,e,g NCT01109004 · Phase 3 · registry result, not featured evidence | 55.3% (n=21) vs 59.1% (n=22) placebo @ 91wkd,f,e,g NCT02440464 · Phase 2 · registry result, not featured evidence |
| PFS time to event · months No placebo or comparator arm | 52.8 monthsc,a,e,b NCT02541383 · Phase 3 · registry result, not featured evidence show 1 more dose46.7 months NCT02541383 · Phase 3 · registry result, not featured evidence | 21.3 monthsa,e,b NCT03748953 · Phase 3 · registry result, not featured evidence 7 other source trialsNA months NCT02389517 · Phase 2 · registry result, not featured evidence · combination NA months NCT02389517 · Phase 2 · registry result, not featured evidence 22.05 months4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination 23.5 months NCT02046070 · Phase 2 · registry result, not featured evidence · combination 14.2 months NCT02046070 · Phase 2 · registry result, not featured evidence · combination 23 months NCT02046070 · Phase 2 · registry result, not featured evidence · combination 5.2 months90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| PFS2 time to event · months | 66.73 vs 42.41 Velcade, Melphalan and Prednisone monthsa,e,b NCT02195479 · Phase 3 · registry result, not featured evidence · combination | 84 vs 80.4 placebo monthsa,e,b NCT02181413 · Phase 3 1 other source trial51.3 vs 50.3 placebo months NCT02312258 · Phase 3 |
| Progressive Disease responder rate · % of participants | 45.6% (n=257) vs 41% (n=254) RVD @ 165wkd,f,e,g NCT01109004 · Phase 3 · registry result, not featured evidence | 44.7% (n=21) vs 36.4% (n=22) placebo @ 91wkd,f,e,g NCT02440464 · Phase 2 · registry result, not featured evidence |
| Time to Next Treatment time to event · months | 66.8 vs 25.9 Velcade, Melphalan and Prednisone monthsa,e,b NCT02195479 · Phase 3 · registry result, not featured evidence · combination 1 other source trial16.13 vs 10.84 Bortezomib + Dexamethasone months NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 | 33.1 vs 27.6 placebo monthsa,e,b NCT02181413 · Phase 3 1 other source trial22.1 vs 16.1 placebo months NCT02312258 · Phase 3 |
| Time to Progression time to event · months | NA vs 19.35 Velcade, Melphalan and Prednisone monthsa,b NCT02195479 · Phase 3 · registry result, not featured evidence · combination 3 other source trialsNA vs 7.29 Bortezomib + Dexamethasone months NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 9.9 vs 12.6 Bortezomib + Dexamethasone months NCT00813150 · Phase 3 · registry result, not featured evidence · combination NA vs NA Lenalidomide+Bortezomib+Dexamethasone months NCT02874742 · Phase 2 · registry result, not featured evidence · combination | 22.4 vs 17.6 placebo monthsa,b NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 4 other source trials45.8 vs 26.8 placebo months NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 26.6 vs 21.4 placebo months NCT02181413 · Phase 3 17.8 vs 9.6 placebo months NCT02312258 · Phase 3 8.4 vs 5.1 Pomalidomide months4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination |
| Time to Progression time to event · months No placebo or comparator arm | 9.3 monthsc,a,b NCT00103506 · Phase 3 · registry result, not featured evidence · combination show 1 more dose6.5 months NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy | 21.3 monthsa,b NCT03748953 · Phase 3 · registry result, not featured evidence 4 other source trials22.57 months4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination 30.9 months NCT02046070 · Phase 2 · registry result, not featured evidence · combination 16.8 months NCT02046070 · Phase 2 · registry result, not featured evidence · combination 32.2 months NCT02046070 · Phase 2 · registry result, not featured evidence · combination |
| Time to Response time to event · months | 0.79 vs 0.82 Velcade, Melphalan and Prednisone monthsa,b NCT02195479 · Phase 3 · registry result, not featured evidence · combination 2 other source trials1.41 vs 1.61 Bortezomib + Dexamethasone months NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0.8 vs 0.8 Lenalidomide+Bortezomib+Dexamethasone months NCT02874742 · Phase 2 · registry result, not featured evidence · combination | 1.02 vs 1.87 placebo monthsa,b NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 1 other source trial2 vs 1.1 Pomalidomide months4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination |
| Time to Response time to event · months No placebo or comparator arm | 1.4 monthsa,b NCT02290431 · Phase 2 · registry result, not featured evidence · combination | 2.1 monthsa,b NCT02046070 · Phase 2 · registry result, not featured evidence · combination |
| VGPR or Better responder rate · % of participants No placebo or comparator arm | 37% (n=147)c,d,a,b NCT00507416 · Phase 3 · registry result, not featured evidence · combination show 2 more doses41% (n=145) NCT00507416 · Phase 3 · registry result, not featured evidence · combination 51% (n=133) NCT00507416 · Phase 3 · registry result, not featured evidence · combination | 50% (n=32)4 mg + 25 mg + 40 mgd,a,b NCT02917941 · Phase 2 · registry result, not featured evidence · combination |
| Dropout rate | 47.3%VELCADE Intravenoush NCT00722566 · Phase 3 show 32 more results45.3%VELCADE Subcutaneous NCT00722566 · Phase 3 n/a: no completion milestone NCT03652064 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02195479 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination —DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —Treatment 1: POM + BTZ + LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination 1.1%Treatment 1: POM+BTZ+LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneSVd Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —SVdX Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 15%Arm A: VELCADE, CYCLOPHOSPHAMIDE, NCT01146834 · Phase 3 · registry result, not featured evidence 0%Arm B: VELCADE & G-CSF NCT01146834 · Phase 3 · registry result, not featured evidence —Arm E: PLERIXAFOR, VELCADE, & G-CS NCT01146834 · Phase 3 · registry result, not featured evidence · combination 0% NCT01109004 · Phase 3 · registry result, not featured evidence 20.7%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneDoxil/Caelyx Plus Velcade (Bortezo NCT00103506 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneVelcade (Bortezomib) Monotherapy NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy 70.2%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 68.3%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 74.9%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 68.1% NCT00813150 · Phase 3 · registry result, not featured evidence · combination 64.3% NCT01801436 · Phase 3 · registry result, not featured evidence 71.6%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · registry result, not featured evidence · combination 1.5%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · registry result, not featured evidence · combination 78.5%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · registry result, not featured evidence · combination 15.4% NCT02874742 · Phase 2 · registry result, not featured evidence · combination 0% NCT02703779 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePart 1 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePart 2 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 87.1% NCT02290431 · Phase 2 · registry result, not featured evidence · combination | 28.1%i NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 show 40 more results49.3%Ixazomib + LenDex NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 —Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 —Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3 18.5% NCT02181413 · Phase 3 n/a: no completion milestone NCT02312258 · Phase 3 — NCT03416374 · Phase 4 · registry result, not featured evidence · combination 0% NCT03748953 · Phase 3 · registry result, not featured evidence — NCT02619682 · Phase 2 · registry result, not featured evidence 3%Arm A (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination 2.8%Arm B (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination 0%Arm C (Higher-dose Ixazomib Citrat NCT01415882 · Phase 2 · registry result, not featured evidence · combination 10.8%Arm D (Ixazomib Citrate, Dexametha NCT01415882 · Phase 2 · registry result, not featured evidence · combination 0%Arm E (Ixazomib Citrate, Cyclophos NCT01415882 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneIxazomib Combination Therapy NCT02924272 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneIxazomib Monotherapy NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy 30%Arm I (Ixazomib Citrate, Lenalidom NCT02389517 · Phase 2 · registry result, not featured evidence · combination 22.7%Arm II (Lenalidomide) NCT02389517 · Phase 2 · registry result, not featured evidence 0% NCT02412228 · Phase 2 · registry result, not featured evidence · combination 0%Arm A (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence 0%Arm B (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence 0%Arm C (Ixazomib, Dexamethasone, Le NCT02765854 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination 14.3% NCT02440464 · Phase 2 · registry result, not featured evidence 70.6%4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination 33.3%4 mg NCT02168101 · Phase 2 · registry result, not featured evidence 66.7%3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 66.7%2.3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 88.9%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 89.7%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 82.4%Ixazomib 4.0 mg + CYC 400 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 95% NCT02499081 · Phase 2 · registry result, not featured evidence 0%4 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination 0%3 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination —90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 0%90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 25%80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 25%70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —VELCADE Intravenoush NCT00722566 · Phase 3 show 32 more results—VELCADE Subcutaneous NCT00722566 · Phase 3 — NCT03652064 · Phase 3 · registry result, not featured evidence — NCT02195479 · Phase 3 · registry result, not featured evidence · combination — NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination —DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —Treatment 1: POM + BTZ + LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination —Treatment 1: POM+BTZ+LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination 0.5%SVd Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —SVdX Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Arm A: VELCADE, CYCLOPHOSPHAMIDE, NCT01146834 · Phase 3 · registry result, not featured evidence —Arm B: VELCADE & G-CSF NCT01146834 · Phase 3 · registry result, not featured evidence —Arm E: PLERIXAFOR, VELCADE, & G-CS NCT01146834 · Phase 3 · registry result, not featured evidence · combination — NCT01109004 · Phase 3 · registry result, not featured evidence 5.5%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Doxil/Caelyx Plus Velcade (Bortezo NCT00103506 · Phase 3 · registry result, not featured evidence · combination —Velcade (Bortezomib) Monotherapy NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy 34.5%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 38.9%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 40.1%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 31.9% NCT00813150 · Phase 3 · registry result, not featured evidence · combination 14.3% NCT01801436 · Phase 3 · registry result, not featured evidence —D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · registry result, not featured evidence · combination —Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · registry result, not featured evidence · combination —Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · registry result, not featured evidence · combination — NCT02874742 · Phase 2 · registry result, not featured evidence · combination — NCT02703779 · Phase 2 · registry result, not featured evidence 33.3%Part 1 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 19%Part 2 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 64.5% NCT02290431 · Phase 2 · registry result, not featured evidence · combination | —i NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 show 40 more results—Ixazomib + LenDex NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 —Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 —Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT02181413 · Phase 3 — NCT02312258 · Phase 3 — NCT03416374 · Phase 4 · registry result, not featured evidence · combination — NCT03748953 · Phase 3 · registry result, not featured evidence — NCT02619682 · Phase 2 · registry result, not featured evidence —Arm A (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination —Arm B (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination —Arm C (Higher-dose Ixazomib Citrat NCT01415882 · Phase 2 · registry result, not featured evidence · combination —Arm D (Ixazomib Citrate, Dexametha NCT01415882 · Phase 2 · registry result, not featured evidence · combination —Arm E (Ixazomib Citrate, Cyclophos NCT01415882 · Phase 2 · registry result, not featured evidence · combination 0%Ixazomib Combination Therapy NCT02924272 · Phase 2 · registry result, not featured evidence · combination 13%Ixazomib Monotherapy NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy 15%Arm I (Ixazomib Citrate, Lenalidom NCT02389517 · Phase 2 · registry result, not featured evidence · combination 4.5%Arm II (Lenalidomide) NCT02389517 · Phase 2 · registry result, not featured evidence — NCT02412228 · Phase 2 · registry result, not featured evidence · combination —Arm A (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence —Arm B (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence —Arm C (Ixazomib, Dexamethasone, Le NCT02765854 · Phase 2 · registry result, not featured evidence · combination —4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination — NCT02440464 · Phase 2 · registry result, not featured evidence 32.4%4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination —4 mg NCT02168101 · Phase 2 · registry result, not featured evidence —3 mg NCT02168101 · Phase 2 · registry result, not featured evidence —2.3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 22.2%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 21.8%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 29.4%Ixazomib 4.0 mg + CYC 400 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination — NCT02499081 · Phase 2 · registry result, not featured evidence —4 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination —3 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination —90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 35.1%VELCADE Intravenoush NCT00722566 · Phase 3 show 32 more results36.1%VELCADE Subcutaneous NCT00722566 · Phase 3 72.1% NCT03652064 · Phase 3 · registry result, not featured evidence 53.8% NCT02195479 · Phase 3 · registry result, not featured evidence · combination 55.1% NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 49.3%DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination 18.8%DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 27.5%VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 63.7%Treatment 1: POM + BTZ + LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination —Treatment 1: POM+BTZ+LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination 55.9%SVd Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 42.4%SVdX Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0%Arm A: VELCADE, CYCLOPHOSPHAMIDE, NCT01146834 · Phase 3 · registry result, not featured evidence 0%Arm B: VELCADE & G-CSF NCT01146834 · Phase 3 · registry result, not featured evidence —Arm E: PLERIXAFOR, VELCADE, & G-CS NCT01146834 · Phase 3 · registry result, not featured evidence · combination 20.6% NCT01109004 · Phase 3 · registry result, not featured evidence 34.6%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination 27.2%Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination 37.7%Doxil/Caelyx Plus Velcade (Bortezo NCT00103506 · Phase 3 · registry result, not featured evidence · combination 33%Velcade (Bortezomib) Monotherapy NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy 53.3%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 50.9%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 58.2%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 29.8% NCT00813150 · Phase 3 · registry result, not featured evidence · combination 100% NCT01801436 · Phase 3 · registry result, not featured evidence 44.8%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · registry result, not featured evidence · combination 28.4%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · registry result, not featured evidence · combination 56.9%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · registry result, not featured evidence · combination 46.5% NCT02874742 · Phase 2 · registry result, not featured evidence · combination 48% NCT02703779 · Phase 2 · registry result, not featured evidence 47.6%Part 1 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 33.1%Part 2 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 45.2% NCT02290431 · Phase 2 · registry result, not featured evidence · combination | 56.8%i NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 show 40 more results—Ixazomib + LenDex NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 65.4%Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 73%Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3 27.4% NCT02181413 · Phase 3 23.7% NCT02312258 · Phase 3 37.8% NCT03416374 · Phase 4 · registry result, not featured evidence · combination 31.4% NCT03748953 · Phase 3 · registry result, not featured evidence 13.3% NCT02619682 · Phase 2 · registry result, not featured evidence 48.5%Arm A (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination 31.4%Arm B (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination 31.4%Arm C (Higher-dose Ixazomib Citrat NCT01415882 · Phase 2 · registry result, not featured evidence · combination 38.9%Arm D (Ixazomib Citrate, Dexametha NCT01415882 · Phase 2 · registry result, not featured evidence · combination 58.3%Arm E (Ixazomib Citrate, Cyclophos NCT01415882 · Phase 2 · registry result, not featured evidence · combination 44.4%Ixazomib Combination Therapy NCT02924272 · Phase 2 · registry result, not featured evidence · combination 52.2%Ixazomib Monotherapy NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy 25%Arm I (Ixazomib Citrate, Lenalidom NCT02389517 · Phase 2 · registry result, not featured evidence · combination 9.1%Arm II (Lenalidomide) NCT02389517 · Phase 2 · registry result, not featured evidence 8.3% NCT02412228 · Phase 2 · registry result, not featured evidence · combination 74.1%Arm A (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence 45.5%Arm B (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence 47.6%Arm C (Ixazomib, Dexamethasone, Le NCT02765854 · Phase 2 · registry result, not featured evidence · combination 55.6%4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination 52.4% NCT02440464 · Phase 2 · registry result, not featured evidence 35.3%4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination 66.7%4 mg NCT02168101 · Phase 2 · registry result, not featured evidence 66.7%3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 0%2.3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 47.2%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 38.5%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 58.8%Ixazomib 4.0 mg + CYC 400 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 40% NCT02499081 · Phase 2 · registry result, not featured evidence 44%4 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination 57.1%3 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination 0%90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 42.1%80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 66.7%70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | show 29 more resultsdiarrhoea 56.3% peripheral sensory neuropathy 55.8% neutropenia 54.8% NCT03652064 · Phase 3 · registry result, not featured evidence neutropenia 50.3% thrombocytopenia 49.7% anaemia 31.8% NCT02195479 · Phase 3 · registry result, not featured evidence · combination thrombocytopenia 59.7% peripheral sensory neuropathy 50.2% diarrhoea 36.2% NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 peripheral sensory neuropathy 60.6% constipation 50.6% asthenia 32.8% NCT02541383 · Phase 3 · registry result, not featured evidence · combination bronchitis 40.6% cough 17% nasopharyngitis 17% NCT02541383 · Phase 3 · registry result, not featured evidence bronchitis 36.5% cough 19.4% nasopharyngitis 17.5% NCT02541383 · Phase 3 · registry result, not featured evidence neutropenia 54% peripheral sensory neuropathy 48.2% thrombocytopenia 39.6% NCT01734928 · Phase 3 · registry result, not featured evidence · combination thrombocytopenia 61.5% nausea 50.3% fatigue 42.1% NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 thrombocytopenia 50% anaemia 45.5% nausea 39.4% NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 anemia 40% nausea 35% platelet count decreased 35% NCT01146834 · Phase 3 · registry result, not featured evidence platelet count decreased 100% anemia 50% generalized muscle weakness 50% NCT01146834 · Phase 3 · registry result, not featured evidence constipation 35.8% nausea 32.3% peripheral sensory neuropathy 24.4% NCT01539083 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 37.9% peripheral sensory neuropathy 36.9% neuropathy peripheral 29.1% NCT01539083 · Phase 3 · registry result, not featured evidence · combination nausea 47.8% diarrhoea 44.7% fatigue 36.2% NCT00103506 · Phase 3 · registry result, not featured evidence · combination nausea 39.3% diarrhoea 38.4% constipation 30.8% NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy insomnia 5.5% weight decreased 2.4% blood sodium decreased 1.8% NCT00507416 · Phase 3 · registry result, not featured evidence · combination leukopenia 7.4% platelet count decreased 4.3% insomnia 3.7% NCT00507416 · Phase 3 · registry result, not featured evidence · combination hyperuricaemia 5.1% insomnia 3.8% cough 3.2% NCT00507416 · Phase 3 · registry result, not featured evidence · combination fatigue 38.3% thrombocytopenia 38.3% diarrhoea 36.2% NCT00813150 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 78.6% white blood cell count decreased 78.6% platelet count decreased 71.4% NCT01801436 · Phase 3 · registry result, not featured evidence thrombocytopenia 56.7% anaemia 44.8% constipation 44.8% NCT03412565 · Phase 2 · registry result, not featured evidence · combination peripheral sensory neuropathy 41.8% constipation 38.8% neutropenia 37.3% NCT03412565 · Phase 2 · registry result, not featured evidence · combination neutropenia 67.7% diarrhoea 49.2% anaemia 40% NCT03412565 · Phase 2 · registry result, not featured evidence · combination fatigue 71.7% upper respiratory tract infection 67.7% diarrhoea 65.7% NCT02874742 · Phase 2 · registry result, not featured evidence · combination diarrhea 58% (placebo 56.9%) nausea 58% (placebo 64.7%) anorexia 54% (placebo 51%) NCT02703779 · Phase 2 · registry result, not featured evidence neutropenia 81% (placebo 38.1%) diarrhoea 61.9% (placebo 36%) thrombocytopenia 61.9% (placebo 46.8%) NCT00401843 · Phase 2 · registry result, not featured evidence · combination neutropenia 60.6% (placebo 38.1%) thrombocytopenia 58.5% (placebo 46.8%) peripheral sensory neuropathy 51.4% (placebo 52.5%) NCT00401843 · Phase 2 · registry result, not featured evidence · combination diarrhoea 80.6% decreased appetite 58.1% thrombocytopenia 54.8% NCT02290431 · Phase 2 · registry result, not featured evidence · combination | i diarrhoea 51.5% (placebo 42.6%) constipation 34.6% (placebo 27.6%) anaemia 34.1% (placebo 29.2%) NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 show 32 more resultsdiarrhoea 77% (placebo 30%) oedema peripheral 55.5% (placebo 32.5%) constipation 48.2% (placebo 38.1%) NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 diarrhoea 41.7% (placebo 30%) oedema peripheral 40.5% (placebo 32.5%) constipation 36.2% (placebo 38.1%) NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 nausea 39.1% (placebo 15.4%) diarrhoea 34.3% (placebo 23.6%) arthralgia 26.6% (placebo 16.6%) NCT02181413 · Phase 3 nausea 27.9% (placebo 8.3%) diarrhoea 23.9% (placebo 12.7%) vomiting 23.9% (placebo 4%) NCT02312258 · Phase 3 diarrhoea 28.9% white blood cell count decreased 24.4% platelet count decreased 20% NCT03416374 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 40% (placebo 25%) diarrhoea 34.3% (placebo 25%) vomiting 25.7% (placebo 0%) NCT03748953 · Phase 3 · registry result, not featured evidence lymphocyte decreased 36.7% lymphocyte decreased 33.3% wbc decreased 33.3% NCT02619682 · Phase 2 · registry result, not featured evidence fatigue 87.9% nausea 84.8% platelet count decreased 81.8% NCT01415882 · Phase 2 · registry result, not featured evidence · combination fatigue 94.3% peripheral sensory neuropathy 88.6% platelet count decreased 74.3% NCT01415882 · Phase 2 · registry result, not featured evidence · combination fatigue 82.9% platelet count decreased 80% peripheral sensory neuropathy 77.1% NCT01415882 · Phase 2 · registry result, not featured evidence · combination fatigue 94.4% diarrhea 80.6% nausea 77.8% NCT01415882 · Phase 2 · registry result, not featured evidence · combination anemia 91.7% fatigue 91.7% lymphocyte count decreased 91.7% NCT01415882 · Phase 2 · registry result, not featured evidence · combination anaemia 33.3% upper respiratory tract infection 33.3% aspartate aminotransferase increased 22.2% NCT02924272 · Phase 2 · registry result, not featured evidence · combination hypertension 17.4% upper respiratory tract infection 13% ankle fracture 8.7% NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy diarrhea 95% fatigue 50% nausea 50% NCT02389517 · Phase 2 · registry result, not featured evidence · combination diarrhea 50% fatigue 40.9% upper respiratory infection 27.3% NCT02389517 · Phase 2 · registry result, not featured evidence platelet count decreased 91.7% lymphocyte count decreased 83.3% rash 83.3% NCT02412228 · Phase 2 · registry result, not featured evidence · combination pneumonia 33.3% colitis 22.2% upper respiratory infection 22.2% NCT02765854 · Phase 2 · registry result, not featured evidence conjunctivits 36.4% bone pain 18.2% pneumonia 18.2% NCT02765854 · Phase 2 · registry result, not featured evidence thrombocytopenia 42.9% neutropenia 19% pneumonia 19% NCT02765854 · Phase 2 · registry result, not featured evidence · combination 4 mg diarrhoea 38.9% peripheral sensory neuropathy 26.4% fatigue 23.6% NCT03170882 · Phase 2 · registry result, not featured evidence · combination pyrexia 14.3% (placebo 4.5%) myalgia 4.8% (placebo 0%) upper respiratory tract infection 4.8% (placebo 0%) NCT02440464 · Phase 2 · registry result, not featured evidence 4 mg + 25 mg + 40 mg constipation 50% upper respiratory tract infection 47.1% diarrhoea 41.2% NCT02917941 · Phase 2 · registry result, not featured evidence · combination 4 mg thrombocytopenia 100% anaemia 66.7% aspartate aminotransferase increased 66.7% NCT02168101 · Phase 2 · registry result, not featured evidence 3 mg gastritis 66.7% thrombocytopenia 66.7% abdominal pain 33.3% NCT02168101 · Phase 2 · registry result, not featured evidence 2.3 mg diarrhoea 100% dry eye 66.7% hypertension 66.7% NCT02168101 · Phase 2 · registry result, not featured evidence anaemia 30.6% diarrhoea 30.6% upper respiratory tract infection 25% NCT02046070 · Phase 2 · registry result, not featured evidence · combination diarrhoea 33.3% upper respiratory tract infection 26.9% anaemia 24.4% NCT02046070 · Phase 2 · registry result, not featured evidence · combination neutropenia 47.1% anaemia 32.4% nausea 29.4% NCT02046070 · Phase 2 · registry result, not featured evidence · combination hyperglycemia 85% hypoalbuminemia 80% fatigue 75% NCT02499081 · Phase 2 · registry result, not featured evidence 4 mg anemia 76% platelet count decreased 76% neutrophil count decreased 68% NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination 3 mg anemia 85.7% lymphocyte count decreased 85.7% white blood cell decreased 85.7% NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bThe assessment timepoint is not available for both results.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dTrial phases differ: Phase 2 versus Phase 3.
- eTreatment context has not been resolved for both arms.
- fPopulation context differs: registered conditions differ.
- gAssessment timepoints differ: 91 weeks versus 165 weeks.
- hPopulation comparability has not been reviewed for 30 of these studies.
- iPopulation comparability has not been reviewed for 36 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Bortezomib
show 4 more results
show 5 more results
show 9 more results
show 9 more results
show 9 more results
show 1 more result
show 1 more result
+ 30 further endpoints in the CSV export.
Ixazomib
show 1 more result
show 1 more result
+ 126 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bortezomib's landscape · Ixazomib's landscape